Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Cancer Res (2019) 79 (4_Supplement): GS3-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS3-02

Published: 15 February 2019

View article

Journal Articles

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L Fehrenbacher, RS Cecchini, CE Geyer, P Rastogi, JP Costantino, JN Atkins, J Polikoff, J-F Boileau, L Provencher, C Stokoe, TD Moore, A Robidoux, V Borges, KS Albain, SM Swain, S Paik, EP Mamounas, N Wolmark

Cancer Res (2018) 78 (4_Supplement): GS1-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS1-02

Published: 15 February 2018

View article

Journal Articles

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

I Krop, J Cortes, K Miller, MT Huizing, L Provencher, L Gianni, S Chan, M Trudeau, J Steinberg, J Sugg, M Liosatos, VE Paton, A Peterson, A Wardley

Cancer Res (2017) 77 (4_Supplement): P4-22-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-08

Published: 15 February 2017

View article

Journal Articles

Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer

H Burris, M Gnant, G Hortobagyi, L Hart, DA Yardley, J Eakle, L Provencher, T Brechenmacher, S Saletan, T Taran, H Rugo

Cancer Res (2013) 73 (24_Supplement): P2-16-17.

DOI: https://doi.org/10.1158/0008-5472.SABCS13-P2-16-17

Published: 15 December 2013

View article

Journal Articles

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

Cancer Res (2013) 73 (24_Supplement): S1-03.

DOI: https://doi.org/10.1158/0008-5472.SABCS13-S1-03

Published: 15 December 2013

View article

Journal Articles

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

L Gianni, G Romieu, M Lichinitser, S Serrano, M Mansutti, X Pivot, I Smirnova, A Moliterni, F Andre, A Chan, O Lipatov, S Chan, A Wardley, R Greil, L Provencher, N Moore, S Prot, V Semiglazov

Cancer Res (2011) 71 (24_Supplement): S4-8.

DOI: https://doi.org/10.1158/0008-5472.SABCS11-S4-8

Published: 15 December 2011

View article

Journal Articles

P1-12-12: Evaluation of Ile655Val HER2 Polymorphism Associated with Cardiac Toxicity Following the Administration of Trastuzumab in Women with Non-Metastatic Breast Cancer.

C Diorio, J Lemieux, M-A Côté, L Provencher, C Nadeau-Larochelle, S Jacob, É Demers, R Tremblay-Lemay, C Saint-Pierre, M Beauchemin, F Barabé, C Laflamme

Cancer Res (2011) 71 (24_Supplement): P1-12-12.

DOI: https://doi.org/10.1158/0008-5472.SABCS11-P1-12-12

Published: 15 December 2011

View article

Journal Articles

P5-20-06: Survival in Women with Breast Cancer Who Used or Did Not Use Scalp Cooling in the Neoadjuvant/Adjuvant Setting.

J Lemieux, L Perron, L Provencher, J Brisson, C Amireault, C Blanchette, E Maunsell

Cancer Res (2011) 71 (24_Supplement): P5-20-06.

DOI: https://doi.org/10.1158/0008-5472.SABCS11-P5-20-06

Published: 15 December 2011

View article

Journal Articles

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

DW Miles, SL de Haas, L Dirix, A Chan, X Pivot, P Tomczak, L Provencher, P Delmar, S. Scherer

Cancer Res (2010) 70 (24_Supplement): P2-16-04.

DOI: https://doi.org/10.1158/0008-5472.SABCS10-P2-16-04

Published: 15 December 2010

View article

Journal Articles

Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD + Cyclophosphamide + Trastuzumab (PLD+C+H), or Doxorubicin + Cyclophosphomide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H).

D. Rayson, T. Suter, S. van der Vegt, C. Jackisch, A. Lluch, J. van den Bosch, G. Lopez Vivanco, A. Mathilde Van Gent, H. Wildiers, L. Provencher, S. Stopatschinskaja, S. Srinivasan, D. Richel

Cancer Res (2009) 69 (24_Supplement): 2085.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-2085

Published: 15 December 2009

View article

Journal Articles

Evaluation of Factors Associated with Recruitment in Breast Cancer Clinical Trials in a Specialized Breast Cancer Centre.

J. Lemieux, G. Forget, O. Brochu, S. Camden, L. Provencher, J. Robert, G. Cantin, C. Desbiens, C. Doyle, J. Morin, B. Poirier

Cancer Res (2009) 69 (24_Supplement): 5122.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-5122

Published: 15 December 2009

View article

Journal Articles

CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).

J. Mackey, S. Hurvitz, J. Crown, J. Forbes, H. Roché, T. Pinter, W. Eiermann, M. Kennedy, F. Priou, L. Provencher, E. Adrover, T. Pienkowski, V. Houé, M. Rupin, M. Martin

Cancer Res (2009) 69 (24_Supplement): 47.

DOI: https://doi.org/10.1158/0008-5472.SABCS-09-47

Published: 15 December 2009

View article

Journal Articles

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

LY Dirix, G Romieu, L Provencher, D Grimes, L de Souza Viana, A Paterson, L Mauriac, A Kirsch, S Pernas, DW Miles

Cancer Res (2009) 69 (2_Supplement): 4116.

DOI: https://doi.org/10.1158/0008-5472.SABCS-4116

Published: 15 January 2009

View article

Journal Articles

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

W Eiermann, T Pienkowski, J Crown, L Chap, M Pawlicki, M Martin, M Saleh, S Sehdev, L Provencher, G Von Minckwitz, V Semiglazov, D Slamon, I Tabah-Fisch, M Buyse, A Riva, H Taupin, G Sauter, J Mackey, on Behalf of the BCIRG005 Investigators

Cancer Res (2009) 69 (2_Supplement): 77.

DOI: https://doi.org/10.1158/0008-5472.SABCS-77

Published: 15 January 2009

View article

NARROW

Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

P1-12-12: Evaluation of Ile655Val HER2 Polymorphism Associated with Cardiac Toxicity Following the Administration of Trastuzumab in Women with Non-Metastatic Breast Cancer.

P5-20-06: Survival in Women with Breast Cancer Who Used or Did Not Use Scalp Cooling in the Neoadjuvant/Adjuvant Setting.

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

Evaluation of Factors Associated with Recruitment in Breast Cancer Clinical Trials in a Specialized Breast Cancer Centre.

CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only